Bioverativ Company Profile (NASDAQ:BIVV)

About Bioverativ (NASDAQ:BIVV)

Bioverativ logoBioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BIVV
  • CUSIP: N/A
  • Web:
  • Market Cap: $6.83787 billion
  • Outstanding Shares: 108,159,000
Average Prices:
  • 50 Day Moving Avg: $60.15
  • 200 Day Moving Avg: $54.89
  • 52 Week Range: $40.00 - $63.99
  • Trailing P/E Ratio: 15.56
  • Foreward P/E Ratio: 22.88
  • P/E Growth: 1.51
Sales & Book Value:
  • Annual Revenue: $954.8 million
  • Price / Sales: 7.21
  • Book Value: $5.41 per share
  • Price / Book: 11.76
  • EBIDTA: $398.8 million
  • Current Ratio: 4.90%
  • Quick Ratio: 4.24%
  • Average Volume: 1.34 million shs.
  • Short Ratio: 2.9
Frequently Asked Questions for Bioverativ (NASDAQ:BIVV)

What is Bioverativ's stock symbol?

Bioverativ trades on the NASDAQ under the ticker symbol "BIVV."

Where is Bioverativ's stock going? Where will Bioverativ's stock price be in 2017?

14 equities research analysts have issued 12-month price targets for Bioverativ's stock. Their forecasts range from $41.00 to $65.00. On average, they expect Bioverativ's share price to reach $55.42 in the next twelve months. View Analyst Ratings for Bioverativ.

What are analysts saying about Bioverativ stock?

Here are some recent quotes from research analysts about Bioverativ stock:

  • 1. According to Zacks Investment Research, "Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States. " (5/16/2017)
  • 2. Stifel Nicolaus analysts commented, "On Friday Bioverativ reported FY16 earnings that included revenue of $887.4 million and net income of $439.6 million. As Biogen reported FY16 numbers that included the Eloctate and Alprolix sales, revenue was in-line with our expectations while expenses were slightly lower in addition to a one-time income tax benefit of $147.7 million. Based on this slightly better than expected expense line, we are raising our target price from $54 to $57. Key questions remain concerning the future research and development spend - which seems slightly high for the collection of clinical trials and selling, general & administrative expenses that decreased Y/Y. We note our change in target price is derived principally from less 2016 SG&A spend than expected ' leaving room for additional PT increase if the R&D line decreases as well. One of the features we like about Bioverativ is the pipeline that seems both interesting and relatively reduced risk and the company anticipates launching a Phase I trial of BIVV001 during 2H17." (3/27/2017)
  • 3. Credit Suisse Group analysts commented, "We are initiating coverage of Bioverativ with an Underperform rating and $45 target price. We think the company's current valuation does not reflect enough risk from new long-acting therapies and novel pipeline competitors: Bioverativ is a pure-play hemophilia company that was spun off from Biogen in early 2017 with commercial assets (Eloctate and Alprolix). We think over the next few years that novel products will emerge from competitors that will pressure sales for its products. Although BIVV has pipeline assets similar to competitors, we think that there is a meaningful difference in development timelines. Competitive datasets over the year could drive volatility in BIVV shares since we don't expect major pipeline catalysts from BIVV this year. If we assume no market share loss from competitors, our FV is $54/share which is limited upside from current levels. Significant upside to the stock is driven by greater confidence in the pipeline which still remains early in our opinion." (3/16/2017)
  • 4. Jefferies Group LLC analysts commented, "As a spin-off of BIIB's hemophilia assets, our positive view on BIVV includes strong cash flow from hemophilia franchise sales (2017 FCF of ~$380M), expanding operating margin (to ~52% in '21 from ~39% in '16) & relatively inexpensive valuation (EV/FCF of ~12x for 2017 vs. ~14x for large-cap biotech). In addition, we see meaningful upside from corporate tax reform if materialized (~+15% to our PT at 20% tax rate vs. current ~38%)." (2/1/2017)

Are investors shorting Bioverativ?

Bioverativ saw a increase in short interest during the month of June. As of June 15th, there was short interest totalling 4,139,061 shares, an increase of 46.0% from the May 31st total of 2,834,453 shares. Based on an average daily trading volume, of 1,028,472 shares, the short-interest ratio is presently 4.0 days. Approximately 3.9% of the company's shares are sold short.

Who are some of Bioverativ's key competitors?

Who are Bioverativ's key executives?

Bioverativ's management team includes the folowing people:

  • Brian S. Posner, Independent Chairman of the Board
  • John G. Cox, Chief Executive Officer, Director
  • John T. Greene, Chief Financial Officer, Executive Vice President, Treasurer
  • Rogerio Vivaldi Coelho M.D., Executive Vice President, Chief Global Therapeutic Operations Officer
  • Lucia Celona, Executive Vice President, Chief Human Resources and Corporate Communications Officer
  • Richard Brudnick, Executive Vice President - Business Development
  • Andrea Marie DiFabio, Executive Vice President, Chief Legal Officer
  • Diantha Duvall, Vice President - Finance, Chief Accounting Officer
  • Alexander J. Denner Ph.D., Independent Director
  • Louis J. Paglia, Independent Director

Who owns Bioverativ stock?

Bioverativ's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include VA PARTNERS I, LLC (3.80%). Company insiders that own Bioverativ stock include Alexander J Denner, Brian S Posner, Diantha Duvall and Louis J Paglia. View Institutional Ownership Trends for Bioverativ.

How do I buy Bioverativ stock?

Shares of Bioverativ can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bioverativ's stock price today?

One share of Bioverativ stock can currently be purchased for approximately $63.62.

MarketBeat Community Rating for Bioverativ (NASDAQ BIVV)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  85 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  155
MarketBeat's community ratings are surveys of what our community members think about Bioverativ and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Bioverativ (NASDAQ:BIVV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 5 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $55.42 (12.89% downside)

Analysts' Ratings History for Bioverativ (NASDAQ:BIVV)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/10/2017Cowen and CompanyUpgradeMarket Perform -> OutperformHighView Rating Details
6/30/2017Jefferies Group LLCReiterated RatingBuyLowView Rating Details
6/28/2017William BlairInitiated CoverageMkt Perform -> Market PerformLowView Rating Details
6/28/2017WedbushReiterated RatingMarket PerformLowView Rating Details
6/23/2017Deutsche Bank AGInitiated CoverageHold$65.00HighView Rating Details
5/24/2017Credit Suisse GroupUpgradeUnderperform -> Neutral$47.00 -> $52.00HighView Rating Details
4/24/2017GabelliDowngradeBuy -> HoldLowView Rating Details
3/31/2017ArgusInitiated CoverageHold -> Hold$51.00HighView Rating Details
3/28/2017Leerink SwannSet Price TargetBuy$62.00LowView Rating Details
3/27/2017Stifel NicolausBoost Price TargetBuy -> Buy$54.00 -> $57.00LowView Rating Details
3/13/2017Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$55.00MediumView Rating Details
2/28/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$44.00 -> $65.00N/AView Rating Details
2/8/2017Morgan StanleyReiterated RatingUnderweight$41.00N/AView Rating Details
2/7/2017Raymond James Financial, Inc.Initiated CoverageStrong-Buy$59.00N/AView Rating Details
(Data available from 7/25/2015 forward)


Earnings History for Bioverativ (NASDAQ:BIVV)
No earnings announcements for this company have been tracked by


Earnings Estimates for Bioverativ (NASDAQ:BIVV)
2017 EPS Consensus Estimate: $2.60
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.59$0.59$0.59
Q2 20172$0.62$0.67$0.65
Q3 20172$0.63$0.69$0.66
Q4 20172$0.64$0.76$0.70
(Data provided by Zacks Investment Research)


Dividend History for Bioverativ (NASDAQ:BIVV)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Bioverativ (NASDAQ:BIVV)
Institutional Ownership Percentage: 89.96%
Insider Trades by Quarter for Bioverativ (NASDAQ:BIVV)
Insider Trades by Quarter for Bioverativ (NASDAQ:BIVV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/28/2017Diantha DuvallInsiderSell818$60.47$49,464.46View SEC Filing  
5/30/2017Alexander J DennerDirectorBuy90,000$55.93$5,033,700.00View SEC Filing  
5/26/2017Louis J PagliaDirectorBuy2,000$57.76$115,520.00View SEC Filing  
5/24/2017Brian S PosnerDirectorBuy2,000$53.86$107,720.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Bioverativ (NASDAQ:BIVV)
Latest Headlines for Bioverativ (NASDAQ:BIVV)
DateHeadline logoBioverativ Inc (NASDAQ:BIVV) Given Average Recommendation of "Hold" by Brokerages - July 25 at 9:34 AM logoMoreno Evelyn V Buys United Technologies Corp, United Technologies Corp, Salesforce. ... - July 22 at 4:30 PM logoTealwood Asset Management Inc Buys Carnival Corp, Cypress Semiconductor Corp, Crown Castle ... - July 19 at 10:47 PM logoIs Sangamo Therapeutics Pointing Toward Success? - July 13 at 3:11 AM logoGuinness Asset Management LTD Buys Oasis Petroleum Inc, Mattel Inc, Cisco Systems Inc, Sells ... - July 11 at 5:40 PM logoCowen Upgrades Bioverativ Shares To Outperform As TNT009 Heats Up - July 11 at 2:36 AM logoCowen Upgrades Bioverativ Inc (BIVV) to Outperform; Positive on ... - - July 10 at 9:32 PM logoCould Biogen Spinoff Bioverativ Have A Blockbuster On Its Hands? - July 10 at 4:31 PM logoBIOVERATIV INC (NASDAQ:BIVV) Expected to Post Quarterly Sales of $264.20 Million - July 9 at 8:30 AM logoBioverativ to Report Second Quarter 2017 Financial Results on August 2, 2017 - July 8 at 9:19 AM logo$0.61 Earnings Per Share Expected for Bioverativ Inc (BIVV) This Quarter - July 7 at 10:20 PM logoBioverativ and Sobi Highlight Commitment to Improving Care for People with Hemophilia at ISTH 2017 Congress - July 6 at 4:09 PM logoNew Data to be Presented at ISTH Underscore Bioverativ’s Commitment to Advance Hemophilia Care - July 6 at 4:09 PM logoQ2 2017 Earnings Estimate for Bioverativ Inc Issued By William Blair (NASDAQ:BIVV) - July 3 at 7:58 AM logoBioverativ Inc (NASDAQ:BIVV) Coverage Initiated by Analysts at William Blair - July 2 at 3:41 PM logoJefferies Group LLC Begins Coverage on BIOVERATIV INC (BIVV) - July 1 at 12:02 PM logoBioverativ Inc (BIVV) Receives Average Rating of "Hold" from Brokerages - June 30 at 11:15 AM logoBioverativ Inc (BIVV) Sees Significant Increase in Short Interest - June 30 at 7:07 AM logoDiantha Duvall Sells 818 Shares of Bioverativ Inc (BIVV) Stock - June 29 at 8:10 PM logoBioverativ Completes Acquisition of True North Therapeutics - June 28 at 8:22 PM logoBioverativ Inc (BIVV) Given Market Perform Rating at Wedbush - June 28 at 8:14 AM logoDeutsche Bank Starts Bioverativ Inc (BIVV) at Hold - - June 24 at 6:06 AM logoHow President Trump Has Sent Biotech Stocks Soaring - June 24 at 6:06 AM logoBioverativ Inc (BIVV) Coverage Initiated at Deutsche Bank AG - June 23 at 8:22 AM logoBioverativ (BIVV) vs. Raptor Pharmaceutical Corp (RPTP) Financial Review - June 23 at 8:18 AM logoNew Strong Sell Stocks for June 20th - June 20 at 4:37 PM logoKennametal, Bioverativ and Apple highlighted as Zacks Bull and Bear of the Day - June 16 at 4:38 PM logoETFs with exposure to Bioverativ, Inc. : June 15, 2017 - June 15 at 5:42 PM logo Brokerages Expect Bioverativ Inc (BIVV) Will Announce Quarterly Sales of $265.30 Million - June 15 at 9:20 AM logoBioverativ announces FDA acceptance of Investigational New Drug Application for BIVV001, a novel, long-acting FVIII hemophilia therapeutic utilizing Amunix XTEN® half-life extension technology - June 14 at 10:47 AM logoZacks: Brokerages Anticipate Bioverativ Inc (BIVV) Will Announce Earnings of $0.59 Per Share - June 13 at 8:08 PM logoBioverativ, Inc. breached its 50 day moving average in a Bearish Manner : BIVV-US : June 13, 2017 - June 13 at 1:02 PM logoBioverativ Announces FDA Acceptance of Investigational New Drug Application for BIVV001 to Treat Hemophilia A - June 12 at 4:59 PM logoOne Insider Just Bought $65 Million Worth of This Expensive Biotech Stock - June 7 at 4:12 PM logoBioverativ: Monster Insider Purchase Indicates Good Times Ahead - June 6 at 2:21 AM logoBioverativ to Present at the Jefferies 2017 Healthcare Conference - June 5 at 9:20 PM logoInsiders Buy the Holdings of VBK ETF - June 5 at 12:43 PM logoBioverativ Inc (BIVV) Receives Consensus Recommendation of "Hold" from Brokerages - June 5 at 9:56 AM logoAlexander J. Denner Acquires 90,000 Shares of Bioverativ Inc (BIVV) Stock - June 1 at 7:32 PM logoBioverativ, Inc. breached its 50 day moving average in a Bearish Manner : BIVV-US : June 1, 2017 - June 1 at 4:21 PM logoInsiders Love Bioverativ, Juno Therapeutics and More - May 31 at 3:58 PM logoLouis J. Paglia Purchases 2,000 Shares of Bioverativ Inc (BIVV) Stock - May 26 at 8:02 PM logoGetting Struck Twice: Acquisitions And Spinouts In Biotech - May 25 at 4:58 PM logoBioverativ Inc (BIVV) Director Buys $107,720.00 in Stock - May 24 at 10:14 PM logoBioverativ Inc (BIVV) Stock Rating Upgraded by Credit Suisse Group AG - May 24 at 12:46 PM logoBioverativ Inc. (BIVV) to Acquire True North Therapeutics - May 24 at 12:28 PM logoBioverativ to Acquire Clinical-Stage Rare Disease Biotechnology Company, True North Therapeutics - May 23 at 11:41 AM logo[$$] Bioverativ to Buy True North Therapeutics for Up to $825 Million - May 23 at 11:41 AM logoBioverativ, Inc. – Value Analysis (NASDAQ:BIVV) : May 19, 2017 - May 19 at 3:52 PM logoBioverativ, Inc. breached its 50 day moving average in a Bearish Manner : BIVV-US : May 18, 2017 - May 18 at 11:45 AM



Bioverativ (BIVV) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by Staff